Bizjournals -- Inhaled drug company Aradigm Corp. lost $5.6 million in the first quarter, up from $4.6 million in the first quarter last year. The Hayward company (OTCBB: ARDM) didn’t have any revenue in the quarter ended March, compared with $416,000 in revenue last year in the same quarter. Aradigm’s operating costs rose compared with last year’s first quarter -- it spent $922,000 more on research and development in this year’s first quarter as it geared up for a clinical trial that started in April. Read article and full press release below.
